PMID- 9894774
OWN - NLM
STAT- MEDLINE
DCOM- 19990323
LR  - 20041117
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 17
IP  - 3
DP  - 1998 Sep
TI  - Possible biological indicators of the response to recombinant tumour necrosis 
      factor alpha in patients with advanced neoplasms.
PG  - 349-54
AB  - Tumour Necrosis Factor alpha (TNF alpha) immunotherapy, in addition to that of 
      Interleukin-2 immunotherapy, represents one of the most promising biotherapies 
      for human neoplasms. In order to identify immunological parameters of prognostic 
      value we studied changes in immune response during first cycle of treatment with 
      hree TNF alpha. The study included 21 locally advanced or metastatic solid tumor 
      patients (M/F:12/9 median age: 57 years, range 38-65) for whom no other standard 
      therapy was available. TNF alpha was administered before midday by a 20-minute 
      intravenous infusion at a dose of 75 microg/day for 5 consecutive days 
      corresponding to one cycle. In the absence of progression two further cycles of 
      TNF alpha were given at 14 day intervals during which the dose was increased by 
      50 microg/day i.e. 2nd cycle- 100 microg/day, 3rd cycle- 150 microg/day. Of 21 
      patients evaluated for both clinical and immunological responses, 4 had complete 
      response and 4 patients had partial response. The present study suggests that TNF 
      alpha biotherapy is not associated with an increase in the number of circulating 
      lymphocytes. Regarding lymphocyte subtype, a slight increase has been observed as 
      far as T lymphocyte subsets are concerned. The CD4/CD8 ratio in cancer patients 
      treated with hree TNF alpha showed significantly lower values than before 
      treatment. On the basis of in vitro experiments an increase in NK cell activation 
      in tissue culture, in addition to an increase of LAK cells, was observed.
FAU - Braczkowski, R
AU  - Braczkowski R
AD  - 5th Dept. of Internal Medicine, Silesian Medical School, Bytom, Poland.
FAU - Zubelewicz, B
AU  - Zubelewicz B
FAU - Romanowski, W
AU  - Romanowski W
FAU - Lissoni, P
AU  - Lissoni P
FAU - Brivio, F
AU  - Brivio F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Antigens, CD)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, CD/blood
MH  - Blood Cell Count
MH  - CD4-CD8 Ratio
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplasms/blood/immunology/pathology/*therapy
MH  - Recombinant Proteins/administration & dosage/adverse effects/therapeutic use
MH  - T-Lymphocyte Subsets/immunology
MH  - Tumor Necrosis Factor-alpha/administration & dosage/adverse effects/*therapeutic 
      use
EDAT- 1999/01/23 00:00
MHDA- 1999/01/23 00:01
CRDT- 1999/01/23 00:00
PHST- 1999/01/23 00:00 [pubmed]
PHST- 1999/01/23 00:01 [medline]
PHST- 1999/01/23 00:00 [entrez]
PST - ppublish
SO  - J Exp Clin Cancer Res. 1998 Sep;17(3):349-54.